Dr. Ke Wang 王珂
Chief Physician
Department of Gynecologic Oncology, Tianjin Medical University Cancer Institute & Hospital, Tianjin
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Diagnosis and treatment of pelvic tumors, with a focus on gynecologic oncology. Expertise includes open surgery, Da Vinci robotic surgery, laparoscopy, molecular targeted therapy, personalized precision medicine, genetic assessment, and multidisciplinary team (MDT) care.
Dr. Wang is Chief Physician and Head of the Department of Gynecologic Oncology at Tianjin Medical University Cancer Institute & Hospital. Holding a Master of Medicine, Dr. Wang has worked in clinical gynecologic oncology at the hospital since graduating in 1993.
Professional roles
- Standing Committee Member, Gynecologic Oncology Professional Committee, China Anti-Cancer Association
- Member, Family Hereditary Tumor Association, China Anti-Cancer Association
- Member, Gynecologic Oncology Expert Committee, Chinese Society of Clinical Oncology (CSCO)
- Vice Chair, Gynecologic Oncology Branch, Tianjin Medical Association
Name order: in Chinese the family name comes first (Wang Ke). Papers usually list the name as Ke Wang or Wang K.
Selected publications
66 papers on PubMed matched by name and affiliation; 14 as first or senior author since 2016. Most recent first- or senior-author papers:
- Front Immunol, 2026 (senior author): An SPP1-centered immune-parenchymal communication axis links macrophage heterogeneity to ovarian cancer prognosis. PubMed 42839972
- iScience, 2026 (senior author): IRX1 suppresses cervical squamous cell carcinoma progression by downregulating ACLY expression to inhibit lipid synthesis. PubMed 42729398
- J Transl Med, 2026 (senior author): SFRP2 drives aerobic glycolysis and tumor progression in ovarian cancer by transcriptional upregulation of PTK2B. PubMed 42337619
- Int J Biol Sci, 2026 (senior author): DHCR24 Drives Ovarian Cancer Chemoresistance Through Lipid Raft-mediated P-gp Stabilization and STAT3 Activation. PubMed 42003908
- Onco Targets Ther, 2025 (senior author): Real-World Experience of Niraparib as Maintenance Therapy in Patients with Newly Diagnosed Advanced Ovarian Cancer: A Single-Center Retrospective Study. PubMed 41185856
- J Ovarian Res, 2025 (senior author): Determination of high-grade serous ovarian cancer stem cell-based subtypes and prognostic model and identification of highly expressed VSIG4 and STAB1 in macrophages. PubMed 40702505
- PeerJ, 2024 (senior author): Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma. PubMed 39494284
- Cancer Genet, 2021 (first author): A hereditary ovarian cancer family with rare pathogenic splicing mutation: Implications for variant interpretation. PubMed 34120093
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that the papers match this doctor's specialty; this check is automatic.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion